prof. dr. L.J. Bont

prof. dr. L.J. Bont

Full Professor
prof. dr. L.J. Bont
  • Center for Translational Immunology (CTI) Research
  • Infectious Diseases Research 2



Louis Bont is a Paediatrician Infectiologist at the Wilhelmina Children’s Hospital in the University Medical Center Utrecht, The Netherlands. He leads the Utrecht RSV Research Group. He is the coordinator of the Interest Group on Respiratory Infections of the European Society of Pediatric Infectious Diseases (ESPID) Research Committee. Dr. Bont is the founder and chairman of ReSViNET, an international RSV Research consortium. He has a strong interest in education of young talented researchers and founded the successful Training of Upcoming Leaders in Pediatric Science (TULIPS) career training program in the Netherlands. Dr. Bont served as advisor of the World Health Organization (WHO), the European Center of Disease Control (ECDC) and the Europarliament.

Louis Bont did his medical training at the Academic Medical Center in Amsterdam (1989-1996). He performed his PhD under the supervision of professor Jan Kimpen and professor Cobi Heijnen at the Wilhelmina Children’s Hospital (1997-2000). He was a post-doc at the Garofalo lab in Galveston, Texas (2000-2001). After returning to Utrecht, he followed the pediatric residency program followed by a pediatric infectious diseases and immunology fellowship. He have led the RSV Research Group since 2003 and became full professor in 2015.

The vision of his research is to combine clinical and basic research to decrease the global burden of RSV infection. The mission of his research group is to improve knowledge of RSV epidemiology, and to develop safe and effective therapeutic and preventive interventions.

In his work collaborate with patients is of highest importance. His work is supported by the RSV Patient Advisory Board (PAB) since 2012. The PAB has reviewed every grant application by the RSV Research Group. PAB members have been interviewed for newspapers and national television on RSV-related subjects.

Louis Bont actively participates as a teacher in the SUMMA program. In addition, he founded the TULIPS program in 2008 to train colleagues and young clinician-scientists.

Since April 1st 2021, Louis has been given a new position as medical scientific division manager of the Children's Division of the Wilhelmina Children's Hospital in Utrecht.

Side Activities

Sideactivities. Payment are always to UMC Utrecht

A. related to RSV infection

Advisory boards, consultancy and steering committees

  • GlaxoSmithKline, Advisory Board (from 2020 onwards), (>€2200.-)
  • Janssen, Global virtual advisory board, (from 2021 onwards), (>€2200.-)
  • Julius Clinical, Advisor research, (from 2021 onwards) (>€2200.-)
  • AstraZeneca, (2019 onward), (>€2200)
  • MSD, Advisory Board, (from 2020 onwards) (>€2200.-)
  • Pfizer (from 2021 onwards), (>€2200.-)
  • Sanofi (from 2020 onwards), (>€2200.-)
  • ESCMID, member executive committee member ESCMID Study Group for Respiratory viruses (from 2022 onwards), (no payment)

Meetings, speaker’s fees, chairing

  • AstraZeneca, (2021 onwards, >€2200.-)        
  • AstraZeneca, Global Synagis filmed interview, (2021), (<€2200.-)
  • GlaxoSmithKline, Virtual meeting, Consultancy, (2021), (<€2200.-)
  • Janssen, speaker (2021), (<€2200.-)
  • Merck Sharp & Dome, Speaker, (2021), (<€2200.-)
  • Merck Sharp & Dome, RSV Passive Approaches and Niche SIE, (2021), (<€2200.-)
  • Merck Sharp & Dome, RSV Airways Hyper-reactivity and Asthma, (2021), (<€2200.-) 
  • Merck Sharp & Dome, (Teleconference) Meetings SAC, (2020-2021), (<€2200.-)
  • Sanofi, RSV Medical Education Meeting with experts, (2021), (<€2200.-) 
  • Sanofi, ReSiNET Symposium, (2021), (>€2200.-)

B. Sideactivities not related to RSV infection

  • AstraZeneca,  Consultant asthma, (2021), (<€2200.-)
  • GSK, Data Safety Monitoring Board VZV vaccine, (2020) (>€2200.-)
  • MediRisk, Expert Consultancy/Advisory, (2019), (<€2200.-)
  • MeMed, Review KOL report, (2021) (>€2200.-)
  • ESGREV executive committee (2022), (no payment)


Potential Conflicts of Interest

Dr. Bont has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. UMCU has received major funding (>€100,000 per industrial partner) for investigator initiated studies from AbbVie, MedImmune, AstraZeneca, Sanofi, Janssen, Pfizer, MSD and MeMed Diagnostics. UMCU has received major funding for the RSV GOLD study from the Bill and Melinda Gates Foundation. UMCU has received major funding as part of the public private partnership IMI-funded RESCEU and PROMISE projects with partners GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. UMCU has received major funding by Julius Clinical for participating in clinical studies sponsored by MedImmune and Pfizer. UMCU received minor funding (€1,000-25,000 per industrial partner) for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic, MabXience, GSK, Novavax, Pfizer, Moderna, Astrazeneca, MSD, Sanofi, Janssen. Dr. Bont is the founding chairman of the ReSViNET Foundation.

Since April 1st 2021, Louis has been given a new position as medical scientific division manager of the Children's Division of the Wilhelmina Children's Hospital in Utrecht.

Fellowship and Awards

Full Professor (“Stimuleringshoogleraarschap”), expected in May 2015

International Congress of Pediatric Pulmunology (CIPP) Award for Contribution to Understanding Childhood Respiratory Disease and Global Medical Education (2013)

Dirkzwager-Assink Fonds Award by Catharijne Stichting for research on RSV bronchiolitis (2010)

Ter Meulen Fonds lecture: It is not all asthma that wheezes. 27e Congres Nederlandse Vereniging voor Kindergeneeskunde, Veldhoven (2005)

ESPID Fellowship Award 2001 Immunopathogenetic mechanisms of RSV infection in the mouse model (2001)

Royal Dutch Academy of Science (Ter Meulen Fonds Stipendium). Immunopathogenetic mechanisms of RSV infection in the mouse model (2000)

Research Output (285)

Biobanking and consenting to research:a qualitative thematic analysis of young people’s perspectives in the North East of England

van der Velden Fabian J.S., Lim Emma, Gills Lily, Broadey Jasmin, Hayes Louise, Roberts Eve, Courtney Jack, Ball Joanne, Herberg Jethro, Galassini Rachel, Emonts Marieke, Levin Michael, Cunnington Aubrey, Kaforou Myrsini, Wright Victoria, Bellos Evangelos, Broderick Claire, Channon-Wells Samuel, Cooray Samantha, De Tisham, D’Souza Giselle, Elorrieta Leire Estramiana, Estrada-Rivadeneyra Diego, Habgood-Coote Dominic, Hamilton Shea, Jackson Heather, Kavanagh James, Marjaneh Mahdi Moradi, Nichols Samuel, Nijman Ruud, Patel Harsita, Pennisi Ivana, Powell Oliver, Reid Ruth, Shah Priyen, Vito Ortensia, Whittaker Elizabeth, Wilson Clare, Womersley Rebecca, Abdulla Amina, Darnell Sarah, Nagelkerke Sietse, van der Flier Michiel, Tissing Wim J.E., Vastert Sebastiaan J., Vijlbrief Daniel C., Bont Louis J., Wolfs Tom F.W., Beudeker Coco R., Hulsmann Sanne C., 5 Jul 2023, In: BMC Medical Ethics. 24 , p. 1-11

Prioritising respiratory syncytial virus prevention in low-income and middle-income countries

Carbonell-Estrany Xavier, Simões Eric Af, Bont Louis J., Paes Bosco A., 1 May 2023, In: The Lancet. Global health. 11 , p. e655-e657

Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection:A multi-country prospective cohort study in Europe

Mao Zhuxin, Li Xiao, Dacosta-Urbieta Ana, Billard Marie Noëlle, Wildenbeest Joanne, Korsten Koos, Martinón-Torres Federico, Heikkinen Terho, Cunningham Steve, Snape Matthew D., Robinson Hannah, Pollard Andrew J., Postma Maarten, Dervaux Benoit, Hens Niel, Bont Louis, Bilcke Joke, Beutels Philippe, 18 Mar 2023, In: Vaccine. 41 , p. 2707-2715 9 p.

RSV immunisation:lessons from the COVID-19 pandemic

Billard Marie Noëlle, Bont Louis Mar 2023, In: The Lancet Child and Adolescent Health. 7 , p. 147-149 3 p.

Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants:Evaluation for six European countries

Getaneh Abraham M., Li Xiao, Mao Zhuxin, Johannesen Caroline K., Barbieri Elisa, van Summeren Jojanneke, Wang Xin, Tong Sabine, Baraldi Eugenio, Phijffer Emily, Rizzo Caterina, van Wijhe Maarten, Heikkinen Terho, Bont Louis, Willem Lander, Jit Mark, Beutels Philippe, Bilcke Joke, 24 Feb 2023, In: Vaccine. 41 , p. 1623-1631 9 p.

Soluble Signal Inhibitory Receptor on Leukocytes-1 Is Released from Activated Neutrophils by Proteinase 3 Cleavage

von Richthofen Helen J., Westerlaken Geertje H.A., Gollnast Doron, Besteman Sjanna, Delemarre Eveline M., Rodenburg Karlijn, Moerer Petra, Stapels Daphne A.C., Andiappan Anand K., Rötzschke Olaf, Nierkens Stefan, Leavis Helen L., Bont Louis J., Rooijakkers Suzan H.M., Meyaard Linde 15 Feb 2023, In: Journal of immunology (Baltimore, Md. : 1950). 210 , p. 389-397 9 p.

Nosocomial RSV-related In-hospital Mortality in Children &lt;5 Years:A Global Case Series

Löwensteyn Yvette N, Willemsen Joukje E, Mazur Natalie I, Scheltema Nienke M, van Haastregt Nynke C J, Buuren Amber A A Ten, van Roessel Ichelle, Scheepmaker Dunja, Nair Harish, van de Ven Peter M, Bont Louis J, 1 Jan 2023, In: The Pediatric infectious disease journal. 42 , p. 1-7 7 p.

Quantifying the RSV immunity debt following COVID-19:a public health matter

Billard Marie Noëlle, Bont Louis J. Jan 2023, In: The Lancet Infectious Diseases. 23 , p. 3-5 3 p.

Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021:an analysis of observational study sequencing data

Wilkins Deidre, Langedijk Annefleur C., Lebbink Robert Jan, Morehouse Christopher, Abram Michael E., Ahani Bahar, Aksyuk Anastasia A., Baraldi Eugenio, Brady Tyler, Chen Albert Tian, Chi Hsin, Choi Eun Hwa, Cohen Robert, Danilenko Daria M., Gopalakrishnan Vancheswaran, Greenough Anne, Heikkinen Terho, Hosoya Mitsuaki, Keller Christian, Kelly Elizabeth J., Kragten-Tabatabaie Leyla, Martinón-Torres Federico, de Los Santos Abiel Homero Mascareñas, Nunes Marta C., Palomino María Angélica, Papenburg Jesse, Pernica Jeffrey M., Richmond Peter, Stein Renato T., Tuffy Kevin M., Verwey Charl, Esser Mark T., Tabor David E., Bont Louis J., Clement Pascale, Gupta Atul, Hashimoto Koichi, Komissarova Kseniya, Laubscher Matt, Lumertz Magali, Priante Elena, Rivero-Calle Irene, Wadia Ushma, Yun Ki Wook 2023, In: The Lancet Infectious Diseases. 23 , p. 856-866 11 p.

Differential isoform expression of Allergin-1 during acute and chronic inflammation

Geerdink Ruben J., Pascoal Ramos Maria Inês, van den Hoogen Luuk L., Radstake Timothy R.D.J., Shibayama Shiro, Shibuya Akira, Bont Louis, Meyaard Linde Dec 2022, In: Immunity, inflammation and disease. 10 , p. 1-9

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet